A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

Name: A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Published: 2014
License: Public Domain

GlaxoSmithKline · 2014

ClinicalTrials.gov · Datasets · License: Public Domain · 2014

Open Source ↗

acute-myeloid-leukemia leukemia lymphoma multiple-myeloma neoplasms oncology

neoplasms, leukemia, acute myeloid leukemia, bet inhibitor, lymphoma, myelodysplastic syndromes, oncology, multiple myeloma, gsk525762, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

Related documents